Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Hormone Therapy Class Labeling Uses Wyeth Template; Appeals Due By March

Executive Summary

Sponsors of hormone replacement therapies have two months to pull together data to justify exemptions to FDA's proposed class labeling incorporating risk information from the Women's Health Initiative

Related Content

Prempro Osteoporosis Use In Older Women May Be Limited To Second-Line
Wyeth Prempro Gets Dementia Warning; FDA Considering HRT Class Labeling
Galen Femring Includes HRT Class Labeling; Launch In June
FDA Hormone Therapy Outreach Will Stress Short-Term, Low-Dose Use
FDA Hormone Therapy Outreach Campaign Urged By Congress In Budget
Berlex Climara Ads For Gallstones, Hypertriglyceridemia Draw FDA Letter
GSK Serevent Safety Label Change Coming Soon; Will Advair Be Affected?
Pfizer’s Women’s Health Initiative: Divest FemHRT And Contraceptive Line
Merck Leads Rebound In Rx Stocks; Upbeat Finish To Historic Bad Year
Prempro Cancer Risk Addressed In 550,000 Physician Letters, Label Review



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts